175 related articles for article (PubMed ID: 24528083)
1. Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Mu XY; Dong XL; Sun J; Ni YH; Dong Z; Li XL; Sun EL; Yi Z; Li G
Asian Pac J Cancer Prev; 2014; 15(1):69-73. PubMed ID: 24528083
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Ali S; El-Rayes BF; Sarkar FH; Philip PA
Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
[TBL] [Abstract][Full Text] [Related]
3. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
4. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Gadgeel SM; Ali S; Philip PA; Ahmed F; Wozniak A; Sarkar FH
Cancer; 2007 Dec; 110(12):2775-84. PubMed ID: 17948911
[TBL] [Abstract][Full Text] [Related]
5. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Chen L; He Y; Huang H; Liao H; Wei W
Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786
[TBL] [Abstract][Full Text] [Related]
6. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Li N; Li H; Su F; Li J; Ma X; Gong P
Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on novel therapies for bronchial carcinoma.
Blackhall F; Papakotoulas PI; Danson S; Thatcher N
Expert Opin Pharmacother; 2005 Jun; 6(7):1157-67. PubMed ID: 15957969
[TBL] [Abstract][Full Text] [Related]
10. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
[TBL] [Abstract][Full Text] [Related]
11. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
16. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
17. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Fidler MJ; Argiris A; Patel JD; Johnson DH; Sandler A; Villaflor VM; Coon J; Buckingham L; Kaiser K; Basu S; Bonomi P
Clin Cancer Res; 2008 Apr; 14(7):2088-94. PubMed ID: 18381949
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Reckamp KL; Koczywas M; Cristea MC; Dowell JE; Wang HJ; Gardner BK; Milne GL; Figlin RA; Fishbein MC; Elashoff RM; Dubinett SM
Cancer; 2015 Sep; 121(18):3298-306. PubMed ID: 26033830
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]